MELAS Study

Description

The purpose of this research is to investigate study drug IW-6463 in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). IW-6463 is not approved by the U.S. Food and Drug Administration for any use.

The study period will last for approximately 75 days and will include at least 3 to 6 on-site visits at the Children’s Hospital of Philadelphia (CHOP), where participants will be provided the study drug and monitored for safety.

For more information, please contact Sara Nguyen at nguyens2@email.chop.edu

For More Information

Contact Us Online

Call (267) 426-6846


Related Centers and Programs